Iron metabolism under rEPO therapy in patients on maintenance hemodialysis.

Abstract

Therapy with recombinant human erythropoietin (rEPO) can correct anemia in RDT patients. However, iron deficiency can develop making treatment unsuccessful. Eighteen non-transfused RDT patients with hematocrit less than 26% were treated with rEPO to raise the HCT to 30-35%; then the dose was individually adjusted to maintain the HCT. The mean HCT rose from… (More)

Topics

  • Presentations referencing similar topics